IN-CUMMINS-INC.
22.9.2022 09:57:25 CEST | Business Wire | Press release
Cummins Inc. (NYSE: CMI) is showcasing its platform of zero-emissions technologies this week at the IAA Transportation show, the world's largest mobility show, in Hannover, Germany. A range of new Cummins technologies and the recently acquired Meritor ePowertrain technologies are available publicly together for the first time. With over a century of experience as a global power leader, Cummins is solidifying its commitment to providing comprehensive zero-emissions technology on a global scale.
"Cummins has deep application expertise, and we are uniquely positioned to deliver solutions that truly fit the needs of commercial applications," said Amy Davis, Vice President and President of New Power at Cummins. "Realizing a net-zero future will require a range of technologies. Our extensive zero-emissions portfolio is how we will meet varied customer demands across the hardest-to-abate industries and make the energy transition possible."
One key zero-emissions product Cummins revealed at IAA is its fourth-generation hydrogen fuel cell engine. Designed to meet the duty-cycle, performance and packaging requirements of medium- and heavy-duty trucks and buses, the fuel cell technology is available in 135 kW single and 270 kW dual modules.
Scania in Europe and Daimler Trucks North America have each announced collaborations with Cummins to develop and integrate these next-generation fuel cell engines into demonstrator vehicles. The systems use fourth-generation variable pressure technology to provide higher power density, power nodes and operating temperatures for easier system integration into vehicles. They also have strong operating cycle efficiency and durability for a lower total cost of ownership.
“We know our customers have diverse needs and complicated duty cycles to support, which is why we focus on continued innovation and improvement,” said Amy Adams, Vice President of Fuel Cell and Hydrogen Technologies at Cummins. “We’re developing hydrogen fuel cell technology that demonstrates the capacity and flexibility required to meet or exceed the power needs for on-highway commercial vehicles – proving hydrogen as a viable solution to decarbonize the economy.”
Attendees at IAA will also get the first glimpse of a drivetrain assembled with a newly introduced Cummins lithium iron phosphate (LFP) battery pack, Meritor’s 17xe ePowertrain and Meritor’s Power Control and Accessory System (PCAS). Cummins recently added the ePowertain and PCAS solutions to its portfolio through its acquisition of Meritor. The ePowertrain leverages market-leading technologies in the axle, motor and inverter, delivering performance, efficiency and packaging advantages at a competitive cost. Additionally, the PCAS provides power where needed and control of necessary sub-systems while reducing packaging size and simplifying integration.
Cummins is adding an LFP battery to its line of lithium-ion battery products to expand support of electrified commercial vehicle applications. The LFP solution gives customers access to faster charging and longer-life batteries, targeting the medium-duty truck and school bus markets. By using a multi-chemistry strategy, Cummins is positioned to expand its manufacturing capacity further and diversify its supply chain, providing customers with more cost-effective electrification solutions.
"We are giving customers options to enable them to adapt to a zero-emissions future faster," said Brian Wilson, General Manager of Electrified Components at Cummins. "With the recent acquisition of Meritor and our new multi-chemistry approach, we will be able to tailor our solutions and offer a one-stop-shop for customers' powertrain needs."
Cummins' portfolio includes four batteries, each of which targets a different duty cycle and use case and complement each other. In addition to the LFP option, this includes three nickel manganese cobalt (NMC) batteries – the BP95E, BP74E and BP30E. The BP95E is Cummins’ next-generation solution that prioritizes greater energy density in applications for customers who need more weight-sensitive solutions or have longer ranges. The BP30E is ideal for meeting limited-space applications and rugged demands, and the BP74E is the foundation for Cummins’ BEV innovation and progress.
Download Cummins product photos.
About Cummins Inc.
Cummins Inc., a global power leader, is a corporation of complementary business segments that design, manufacture, distribute and service a broad portfolio of power solutions. The company’s products range from diesel, natural gas, electric and hybrid powertrains, and powertrain-related components including filtration, aftertreatment, turbochargers, fuel systems, controls systems, air handling systems, automated transmissions, electric power generation systems, batteries, electrified power systems, hydrogen generation and fuel cell products. Headquartered in Columbus, Indiana (U.S.), since its founding in 1919, Cummins employs approximately 59,900 people committed to powering a more prosperous world through three global corporate responsibility priorities critical to healthy communities: education, environment, and equality of opportunity. Cummins serves its customers online, through a network of company-owned and independent distributor locations, and through thousands of dealer locations worldwide and earned about $2.1 billion on sales of $24.0 billion in 2021. See how Cummins is powering a world that is always on by accessing news releases and more information at https://www.cummins.com/always-on.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005980/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
